



## Policy on Collaborations with Pharmaceutical Companies

At Cavernoma Alliance UK, our mission is to support individuals affected by cavernoma and to advocate for advancements in treatment and care. We recognise the potential benefits of collaborating with pharmaceutical companies to further these goals. However, we are committed to ensuring that such partnerships are conducted with transparency, integrity, and in alignment with our values and the best interests of our community.

### Funding Limitations

To maintain our independence and ensure that no single entity has undue influence over our activities, we adhere to the following funding limitations:

- **Aggregate Funding Cap:** We will not accept cumulative donations from pharmaceutical companies that exceed 20% of our total annual income.
- **Individual Donation Limit:** No donation from a single pharmaceutical company will exceed 10% of our total annual income.

These measures are in place to diversify our funding sources and to prevent reliance on any single contributor. They will be reviewed annually by the Board of Trustees.

### Diverse Sponsorship

Wherever possible, we seek sponsorship from multiple pharmaceutical companies for our initiatives. This approach promotes a balanced and unbiased perspective in our programmes and activities, ensuring that our community receives comprehensive and impartial information.

### Compliance with the ABPI Code of Practice

Our collaborations with pharmaceutical companies are guided by the principles set forth in the Association of the British Pharmaceutical Industry (ABPI) Code of Practice. In accordance with the Code, we ensure that:

- **Written Agreements:** All partnerships are formalised through written agreements that clearly define the nature and objectives of the collaboration, roles and responsibilities, funding amounts, and timeframes.
- **Transparency and Disclosure:** We publicly disclose any financial support or significant indirect/non-financial assistance received from pharmaceutical companies. This includes the company's name, the amount, the date, and a brief description of the activity, as recommended by the ABPI.

- **Independence and Integrity:** We maintain full control over our activities and content, ensuring that our independence is not compromised and that there is no undue influence from any pharmaceutical company.

### **Use of Funds**

Funds received from pharmaceutical companies are utilised strictly for purposes specified in the written agreements. We do not use such funds to promote or endorse any company's products, nor do we engage in activities that could create a conflict of interest. All expenditures align with our charitable aims and comply with relevant guidelines. We will never accept funding for salary costs.

Last updated January 2025